MTSS2 and central nervous system cancer: Revalidation of the knockdown efficiency of this target with three different Mtss2-shRNA (Mtss2-shRNA1-3) in rat C6 glioma cells showed a 70–80% reduction of Mtss2 mRNA and protein levels with Mtss2-shRNA3 (Figure 1—figure supplement 1).